Aurora Cannabis (NASDAQ:ACB) Releases Quarterly Earnings Results, Beats Estimates By $999.07 EPS

Aurora Cannabis (NASDAQ:ACB) released its quarterly earnings data on Thursday. The company reported $999.00 EPS for the quarter, topping the consensus estimate of ($0.07) by $999.07, Zacks reports. Aurora Cannabis had a negative return on equity of 0.04% and a negative net margin of 23.46%.

Aurora Cannabis Stock Down 2.7%

Shares of NASDAQ:ACB opened at $3.29 on Thursday. Aurora Cannabis has a 1 year low of $3.07 and a 1 year high of $6.66. The company has a market cap of $201.82 million, a PE ratio of -3.05 and a beta of 0.53. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 1.48. The stock’s 50-day moving average is $3.46 and its 200 day moving average is $3.85.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Jones Financial Companies Lllp increased its holdings in Aurora Cannabis by 9,615.6% during the 1st quarter. Jones Financial Companies Lllp now owns 52,270 shares of the company’s stock valued at $229,000 after purchasing an additional 51,732 shares during the period. Mackenzie Financial Corp increased its holdings in Aurora Cannabis by 15.0% during the 3rd quarter. Mackenzie Financial Corp now owns 33,909 shares of the company’s stock valued at $202,000 after purchasing an additional 4,422 shares during the period. Brooklyn Investment Group purchased a new position in Aurora Cannabis during the 4th quarter valued at about $197,000. Virtu Financial LLC purchased a new position in Aurora Cannabis during the 4th quarter valued at about $177,000. Finally, State of Wyoming bought a new stake in Aurora Cannabis during the 4th quarter valued at approximately $168,000. Hedge funds and other institutional investors own 47.63% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Weiss Ratings upgraded Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Wall Street Zen upgraded Aurora Cannabis from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Aurora Cannabis has a consensus rating of “Hold”.

About Aurora Cannabis

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.